Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth

One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of costly cocktails to reduce antibody resistance. We engineered two bispecific antibodies (bsAbs) using distinct designs and compared them with parental antibodies and their cocktail. Single molecules of both bs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Zhiqiang, Xie, Xuping, Lin, Jianqing, Gao, Peng, El Sahili, Abbas, Su, Hang, Liu, Yang, Ye, Xiaohua, Li, Xin, Fan, Xuejun, Goh, Boon Chong, Xiong, Wei, Boyd, Hannah, Muruato, Antonio E., Deng, Hui, Xia, Hongjie, Jing, Zou, Kalveram, Birte K., Menachery, Vineet D., Zhang, Ningyan, Lescar, Julien, Shi, Pei-Yong, An, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820655/
https://www.ncbi.nlm.nih.gov/pubmed/35132410
http://dx.doi.org/10.1101/2022.02.01.478504

Ejemplares similares

Ejemplares similares